Publications by authors named "Quanhua Ding"
Objective: To determine the effect of sanguinarine on the biological behavior of hepatocellular carcinoma (HCC) cells via regulating the miR-497-5p/cyclin-dependent kinase 4 (CDK4) axis.
Methods: Swiss Target Prediction was used for target prediction of sanguinarine. The targets were analyzed with KEGG enrichment analysis, and CDK4 was included in this study.
The immunomodulatory properties of mesenchymal stem cells (MSCs) have been broadly investigated in research on inflammatory diseases including ulcerative colitis. Treating MSCs with an inflammatory stimulus before transplantation is an adaptive strategy that helps MSCs survive in areas of inflammation and promotes the regulation of local immune responses. This study aimed to examine the effects of pretreating bone marrow MSCs (BMSCs) with Interleukin-6 (IL-6) on attenuation of dextran sulfate sodium (DSS)-induced ulcerative colitis in rats.
View Article and Find Full Text PDFObjective: To investigate the effects of alendronate combined with local radiotherapy on the level of serum Akt/GSK3β and bone metabolism in patients of primary liver cancer with bone metastases.
Methods: Clinical data of 68 patients of primary liver cancer with bone metastases and treated in Shanghai General Hospital, a hospital affiliated to Shanghai Jiao Tong University School of Medicine, were retrospectively analyzed. According to the different surgical methods, the patients were divided into a control group, with 33 cases treated with local radiotherapy plus Oxycodone hydrochloride extended-release tablets, and a study group, with 35 cases treated with alendronate combined with local radiotherapy.
Article Synopsis
- DEB-TACE, known for its steady drug release and low side effects, shows promising results when combined with radiofrequency ablation (RFA) for treating primary hepatocellular carcinoma (HCC).
- A study involving 76 patients aimed to assess the treatment's efficacy and survival outcomes, comparing those with untreated HCC (Group A) and hepatectomy patients (Group C).
- Results indicated similar treatment effectiveness between Groups A and C, with Group A showing lower liver enzyme levels and absence of operational-related deaths, suggesting DEB-TACE combined with RFA is a viable option for HCC management with potential benefits.